Summarized by Masters of Longevity from PR Newswire.
Three-year follow-up from a Phase II trial reports durable suprachoroidal gene therapy benefits for non-proliferative diabetic retinopathy after one in-office administration.
Key Takeaways
- Sixty percent of Dose Level 3 participants with three-year visits achieved greater than 2-step DRSS improvement without additional DR treatment.
- No sura-vec–related safety signals or intraocular inflammation were observed through three years with prophylactic topical steroids.
- Participants who showed 1-step DRSS improvement at one year often progressed to greater than 2-step improvement by three years without supplemental anti-VEGF injections.
